Fukuhara Hiroshi, Matsumoto Akihiko, Kitamura Tadaichi, Takeuchi Takumi
Department of Urology, Faculty of Medicine, University of Tokyo, Japan.
BJU Int. 2006 Jun;97(6):1314-21. doi: 10.1111/j.1464-410X.2006.06180.x.
To examine the significance of the thymus and the neutralization of interleukin-2 (IL-2) in treating renal cancer, as the involvement of immunoregulatory cells in tumour development in vivo is well known, naturally occurring CD25+ CD4+ T cells possess potent immunoregulatory functions, and they are of thymic origin dependent on IL-2.
We first tested activity against mouse renal cell carcinoma (RENCA) cells by adoptively transferring splenocytes of euthymic Balb/c mice depleted of CD25+ cells into athymic Balb/c nude mice bearing established macroscopic RENCA tumours. Second, we tested the anti-RENCA activity in euthymic mice bearing macroscopic RENCA tumours by neutralizing IL-2.
The intravenous administration of CD25+ cell-depleted splenocytes of euthymic Balb/c mice initiated the retardation of macroscopic RENCA tumours subcutaneously established in athymic Balb/c mice. The tumour site showed massive lymphocyte infiltration of mainly CD4+ T cells. By eliminating either the CD4+ cells, CD8+ cells, or natural killer (NK) cells with antibodies after the adoptive transfer of CD25+ cell-depleted splenocytes of euthymic Balb/c mice, macroscopic RENCA tumour retardation was abrogated. The growth of macroscopic RENCA tumour established in euthymic Balb/c mice was also retarded with IL-2 neutralization alone by anti-IL-2 monoclonal antibody (mAb), as well as co-administration of anti-IL-2 mAb and anti-CD25 mAb compared with that of the controls given vehicle. After tumour inoculation, peri- and intratumoral infiltration of CD4+ and CD8+ T cells was very prominent in RENCA tumours in hosts given anti-IL-2 mAb, regardless of the administration of anti-CD25 mAb. Two x 10(5) units of recombinant human IL-2 reverted the retardation of RENCA tumour growth caused by the anti-IL-2 mAb. IL-2 neutralization alone in euthymic Balb/c mice with no tumour inoculation did not suppress splenic CD25+ CD4+ T cells.
Both the intravenous administration of CD25+ cell-depleted splenocytes of euthymic Balb/c mice into athymic Balb/c nude mice and IL-2 blocking with anti-IL-2 mAb in euthymic Balb/c mice retarded the growth of macroscopic RENCA tumours in vivo.
鉴于免疫调节细胞在体内肿瘤发展中的作用已为人熟知,天然存在的CD25+CD4+T细胞具有强大的免疫调节功能且它们起源于胸腺并依赖白细胞介素-2(IL-2),研究胸腺及IL-2中和在治疗肾癌中的意义。
我们首先通过将去除CD25+细胞的正常胸腺Balb/c小鼠的脾细胞过继转移至已形成肉眼可见RENCA肿瘤的无胸腺Balb/c裸鼠体内,来测试其对小鼠肾细胞癌(RENCA)细胞的活性。其次,我们通过中和IL-2来测试在已形成肉眼可见RENCA肿瘤的正常胸腺小鼠中的抗RENCA活性。
静脉注射去除CD25+细胞的正常胸腺Balb/c小鼠的脾细胞,可使皮下接种于无胸腺Balb/c小鼠的肉眼可见的RENCA肿瘤生长减缓。肿瘤部位可见大量主要为CD4+T细胞的淋巴细胞浸润。在用去除CD25+细胞的正常胸腺Balb/c小鼠的脾细胞进行过继转移后,通过抗体清除CD4+细胞、CD8+细胞或自然杀伤(NK)细胞,肉眼可见的RENCA肿瘤生长减缓被消除。单独用抗IL-2单克隆抗体(mAb)中和IL-2,以及与抗CD25 mAb联合给药,均可使正常胸腺Balb/c小鼠体内已形成的肉眼可见的RENCA肿瘤生长减缓,与给予赋形剂的对照组相比。肿瘤接种后,无论是否给予抗CD25 mAb,在给予抗IL-2 mAb的宿主的RENCA肿瘤中,肿瘤周围和肿瘤内CD4+和CD8+T细胞浸润都非常显著。2×10(5)单位的重组人IL-2可逆转抗IL-2 mAb导致的RENCA肿瘤生长减缓。在未接种肿瘤的正常胸腺Balb/c小鼠中单独中和IL-2不会抑制脾脏CD25+CD4+T细胞。
将去除CD25+细胞的正常胸腺Balb/c小鼠的脾细胞静脉注射到无胸腺Balb/c裸鼠体内,以及在正常胸腺Balb/c小鼠中用抗IL-2 mAb阻断IL-2,均可在体内减缓肉眼可见RENCA肿瘤的生长。